Ipca, Ranbaxy ink deal for US market

Ipca Laboratories has entered into a strategic alliance with Ranbaxy Pharmaceuticals, USA, a wholly-owned subsidiary of Ranbaxy Laboratories.

According to a release issued by Ipca to the BSE today, the company will develop a number of generic prescription products that will be marketed and distributed by Ranbaxy in the US.

"The first product to be launched under the alliance will be Furosemide tablets 20mg, 40mg, and 80mg, which received USFDA approval on September 18, 2006," the release added.

Ipca will manufacture such products at its facilities in India, and is also setting up a Rs 60 crore facility at the Indore SEZ.